Patents by Inventor Lex M. Cowsert

Lex M. Cowsert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antisense inhibition of human Akt-2 expression
    Patent number: 6043090
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Akt-2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Akt-2. Methods of using these compounds for modulation of Akt-2 expression and for treatment of diseases associated with expression of Akt-2 are provided.
    Type: Grant
    Filed: March 23, 1999
    Date of Patent: March 28, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Antisense modulation of liver glycogen phosphorylase expression
    Patent number: 6043091
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of liver glycogen phosphorylase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding liver glycogen phosphorylase. Methods of using these compounds for modulation of liver glycogen phosphorylase expression and for treatment of diseases associated with expression of liver glycogen phosphorylase are provided.
    Type: Grant
    Filed: July 19, 1999
    Date of Patent: March 28, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Antisense inhibition of Smad5 expression
    Patent number: 6040178
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Smad5. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Smad5. Methods of using these compounds for modulation of Smad5 expression and for treatment of diseases associated with expression of Smad5 are provided.
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: March 21, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Antisense inhibition of G-alpha-i2 expression
    Patent number: 6040179
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of G-alpha-i2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G-alpha-i2. Methods of using these compounds for modulation of G-alpha-i2 expression and for treatment of diseases associated with expression of G-alpha-i2 are provided.
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: March 21, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventor: Lex M. Cowsert
  • Antisense inhibition of SMAD2 expression
    Patent number: 6037142
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Smad2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Smad2. Methods of using these compounds for modulation of Smad2 expression and for treatment of diseases associated with expression of Smad2 are provided.
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: March 14, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Antisense inhibition of integrin beta 3 expression
    Patent number: 6037176
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of integrin beta 3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding integrin beta 3. Methods of using these compounds for modulation of integrin beta 3 expression and for treatment of diseases associated with expression of integrin beta 3 are provided.
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: March 14, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Brett P. Monia, Lex M. Cowsert
  • Antisense inhibition of MAP kinase kinase 6 expression
    Patent number: 6033910
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MAP kinase kinase 6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MAP kinase kinase 6. Methods of using these compounds for modulation of MAP kinase kinase 6 expression and for treatment of diseases associated with expression of MAP kinase kinase 6 are provided.
    Type: Grant
    Filed: July 19, 1999
    Date of Patent: March 7, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Antisense inhibition of PEPCK-mitochondrial expression
    Patent number: 6030837
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PEPCK-mitochondrial. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PEPCK-mitochondrial. Methods of using these compounds for modulation of PEPCK-mitochondrial expression and for treatment of diseases associated with expression of PEPCK-mitochondrial are provided.
    Type: Grant
    Filed: August 3, 1999
    Date of Patent: February 29, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Robert McKay, Madeline M. Butler, Lex M. Cowsert
  • Antisense modulation of RhoC expression
    Patent number: 6030786
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of RhoC. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding RhoC. Methods of using these compounds for modulation of RhoC expression and for treatment of diseases associated with expression of RhoC are provided.
    Type: Grant
    Filed: September 18, 1998
    Date of Patent: February 29, 2000
    Assignee: Isis Pharmaceuticals, Inc.
    Inventor: Lex M. Cowsert
  • Antisense modulation of Ship-2 expression
    Patent number: 6025198
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Ship-2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Ship-2. Methods of using these compounds for modulation of Ship-2 expression and for treatment of diseases associated with expression of Ship-2 are provided.
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: February 15, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert
  • Antisense modulation of PTEN expression
    Patent number: 6020199
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PTEN. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTEN. Methods of using these compounds for modulation of PTEN expression and for treatment of diseases associated with expression of PTEN are provided.
    Type: Grant
    Filed: July 21, 1999
    Date of Patent: February 1, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Antisense modulation of RIP-1 expression
    Patent number: 6020198
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of RIP-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding RIP-1. Methods of using these compounds for modulation of RIP-1 expression and for treatment of diseases associated with expression of RIP-1 are provided.
    Type: Grant
    Filed: September 25, 1998
    Date of Patent: February 1, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert
  • Antisense modulation of FADD expression
    Patent number: 6015712
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of FADD. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding FADD. Methods of using these compounds for modulation of FADD expression and for treatment of diseases associated with expression of FADD are provided.
    Type: Grant
    Filed: July 19, 1999
    Date of Patent: January 18, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Brenda F. Baker, Hong Zhang, Lex M. Cowsert
  • Antisense modulation of Smad4 expression
    Patent number: 6013787
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Smad4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Smad4. Methods of using these compounds for modulation of Smad4 expression and for treatment of diseases associated with expression of Smad4 are provided.
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: January 11, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Antisense modulation of Smad3 expression
    Patent number: 6013788
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Smad3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Smad3. Methods of using these compounds for modulation of Smad3 expression and for treatment of diseases associated with expression of Smad3 are provided.
    Type: Grant
    Filed: April 9, 1999
    Date of Patent: January 11, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Antisense inhibition of human Smad1 expression
    Patent number: 6013522
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Smad1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Smad1. Methods of using these compounds for modulation of Smad1 expression and for treatment of diseases associated with expression of Smad1 are provided.
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: January 11, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Antisense modulation of Jun N-terminal kinase kinase-1 expression
    Patent number: 6010906
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Jun N-terminal Kinase Kinase-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Jun N-terminal Kinase Kinase-1. Methods of using these compounds for modulation of Jun N-terminal Kinase Kinase-1 expression and for treatment of diseases associated with expression of Jun N-terminal Kinase Kinase-1 are provided.
    Type: Grant
    Filed: July 21, 1999
    Date of Patent: January 4, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Donna T. Ward, Lex M. Cowsert
  • Antisense inhibition of TNFR1 expression
    Patent number: 6007995
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of TNFR1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding TNFR1. Methods of using these compounds for modulation of TNFR1 expression and for treatment of diseases associated with expression of TNFR1 are provided.
    Type: Grant
    Filed: June 26, 1998
    Date of Patent: December 28, 1999
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brenda F. Baker, Lex M. Cowsert
  • Antisense inhibition of EGR-1 expression
    Patent number: 6008048
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of EGR-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding EGR-1. Methods of using these compounds for modulation of EGR-1 expression and for treatment of diseases associated with expression of EGR-1 are provided.
    Type: Grant
    Filed: December 4, 1998
    Date of Patent: December 28, 1999
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Antisense modulation of phospholipase A2 group IV expression
    Patent number: 6008344
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Phospholipase A2 Group IV. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Phospholipase A2 Group IV. Methods of using these compounds for modulation of Phospholipase A2 Group IV expression and for treatment of diseases associated with expression of Phospholipase A2 Group IV are provided.
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: December 28, 1999
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert